Shots:
- The P-II KINETIC study involves assessing the efficacy, safety, and tolerability of SAGE-324 (60mg, qd) vs PBO in 69 patients in a ratio (1:1) aged 18-80yrs. with essential tremor for 29 days
- The study met its 1EPs i.e reduction from baseline in TETRAS Performance Subscale Item 4 upper limb tremor score @29day (36% vs 21%), ADL score is numerically superior at all time points, consistent safety profile with previously reported data
- In a more severe population, a reduction from baseline in tetras Upper Limb Item 4 >12, SAGE-32 demonstrated a (41% vs 18%) reduction from baseline in upper limb tremor amplitude
Click here to read full press release/ article | Ref: Businesswire | Image: Businesswire
The post Sage and Biogen Report Results of SAGE-324 in P-II KINETIC Study for Essential Tremor first appeared on PharmaShots.
